DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.
DiogenX has raised $36.8M in total funding. The most recent round was Series A. The last funding was announced in May 2023.
DiogenX's investors include Eli Lilly, Omnes Capital, Boehringer Ingelheim Venture Fund, AdBio partners, Sunstone Life Science Ventures.
DiogenX is headquartered in Marseille, France.
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators.
DiogenX is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"DiogenX — Funding & Investors." VCBacked, May 10, 2023, https://www.vcbacked.co/company/diogenx. Accessed September 13, 2026.
VCBacked. (2023). DiogenX — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/diogenx
{{cite web |title=DiogenX — Funding & Investors |url=https://www.vcbacked.co/company/diogenx |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated